Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10528633,half-life,The half-life in vitreous was 5.6 days for the full-length antibody and 3.2 days for the Fab antibody.,"Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528633/),d,5.6,72,DB00072,Trastuzumab
,10528633,half-life,The half-life in vitreous was 5.6 days for the full-length antibody and 3.2 days for the Fab antibody.,"Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528633/),d,3.2,73,DB00072,Trastuzumab
,20823293,elimination half-life,"The elimination half-life of AHM from the plasma was 7.56 h at 2 mg/kg and 28.6 h at 20 mg/kg, which was shorter than that observed for other therapeutic humanized monoclonal antibodies, such as trastuzumab and bevacizumab.",Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823293/),h,7.56,5115,DB00072,Trastuzumab
,20823293,elimination half-life,"The elimination half-life of AHM from the plasma was 7.56 h at 2 mg/kg and 28.6 h at 20 mg/kg, which was shorter than that observed for other therapeutic humanized monoclonal antibodies, such as trastuzumab and bevacizumab.",Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20823293/),h,28.6,5116,DB00072,Trastuzumab
,29356543,t1/2,"As a proof-of-concept, a HER2-targeting trastuzumab immunoconjugate was created bearing both a monomethyl auristatin E (MMAE) toxin as well as the long-lived positron-emitting radiometal 89Zr ( t1/2 ≈ 3.3 days).",Site-Specifically Labeled Antibody-Drug Conjugate for Simultaneous Therapy and ImmunoPET. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29356543/),d,3.3,7968,DB00072,Trastuzumab
,29356543,uptake,"The site-specifically dual-labeled construct enabled the clear visualization of tumor tissue via PET imaging, producing tumoral uptake of ∼70%ID/g.",Site-Specifically Labeled Antibody-Drug Conjugate for Simultaneous Therapy and ImmunoPET. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29356543/),%,∼70,7969,DB00072,Trastuzumab
,19318484,maximum tolerated dose,"Dose-limiting toxicity was grade 3 diarrhea, which occurred in one patient treated with 180 mg and in four patients treated with 400 mg neratinib; hence, the maximum tolerated dose was determined to be 320 mg.","A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19318484/),mg,320,10487,DB00072,Trastuzumab
,32306807,T1/2,"Following iv administration of DXd, it was rapidly cleared from the circulation (T1/2; 1.35 h) and excreted mainly through faeces as its intact form.","Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32306807/),h,1.35,14298,DB00072,Trastuzumab
,9704716,response duration,"The median response duration was 5.3 months (range, 1.6-18).",Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9704716/),month,5.3,18458,DB00072,Trastuzumab
,25459109,distribution half-life (t1/2α),(111)In-BzDTPA-pertuzumab exhibited a biphasic elimination from the blood with a distribution half-life (t1/2α) of 3.8h and an elimination half-life (t1/2β) of 228.2h.,"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459109/),h,3.8,22880,DB00072,Trastuzumab
,25459109,elimination half-life (t1/2β),(111)In-BzDTPA-pertuzumab exhibited a biphasic elimination from the blood with a distribution half-life (t1/2α) of 3.8h and an elimination half-life (t1/2β) of 228.2h.,"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459109/),h,228.2,22881,DB00072,Trastuzumab
,25459109,radiation absorbed dose,The projected whole-body radiation absorbed dose in humans was 0.05mSv/MBq corresponding to a total of 16.8mSv for three separate administrations of (111)In-BzDTPA-pertuzumab (111MBq) planned for the Phase I/II trial.,"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459109/),[msv] / [Mbq],0.05,22882,DB00072,Trastuzumab
,25459109,radiation absorbed dose,The projected whole-body radiation absorbed dose in humans was 0.05mSv/MBq corresponding to a total of 16.8mSv for three separate administrations of (111)In-BzDTPA-pertuzumab (111MBq) planned for the Phase I/II trial.,"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459109/),msv,16.8,22883,DB00072,Trastuzumab
,29198065,t ½,Bioorthogonal reaction between tetrazine and trans-cyclooctene (TCO) was used for tracing cetuximab and trastuzumab in vivo with a fluorine-18 (t ½ = 109.8 min) labelled tracer.,Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198065/),min,109.8,26440,DB00072,Trastuzumab
,29198065,lag time,"With cetuximab, the highest tumour-to-blood ratios were achieved when the lag time between antibody and tracer injections was 72 h.",Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198065/),h,72,26441,DB00072,Trastuzumab
,29198065,tumour uptake,"For both antibodies, the tumour could be clearly visualized in the PET images with the highest tumour uptake of 3.7 ± 0.1%ID/g for cetuximab and 1.5 ± 0.1%ID/g for trastuzumab as quantified by ex vivo biodistribution.",Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198065/),[%id] / [g],3.7,26442,DB00072,Trastuzumab
,29198065,tumour uptake,"For both antibodies, the tumour could be clearly visualized in the PET images with the highest tumour uptake of 3.7 ± 0.1%ID/g for cetuximab and 1.5 ± 0.1%ID/g for trastuzumab as quantified by ex vivo biodistribution.",Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198065/),[%id] / [g],1.5,26443,DB00072,Trastuzumab
,30082554,Cmax,"For reference and study trastuzumab products, mean Cmax of 229.02 and 210.68 μg/mL and AUC0-336 of 24298.29 and 25809.33 (μg × h/mL), respectively, were obtained.",A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082554/),[μg] / [ml],229.02,34082,DB00072,Trastuzumab
,30082554,Cmax,"For reference and study trastuzumab products, mean Cmax of 229.02 and 210.68 μg/mL and AUC0-336 of 24298.29 and 25809.33 (μg × h/mL), respectively, were obtained.",A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082554/),[μg] / [ml],210.68,34083,DB00072,Trastuzumab
,30082554,AUC0-336,"For reference and study trastuzumab products, mean Cmax of 229.02 and 210.68 μg/mL and AUC0-336 of 24298.29 and 25809.33 (μg × h/mL), respectively, were obtained.",A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082554/),[h·μg] / [ml],24298.29,34084,DB00072,Trastuzumab
,30082554,AUC0-336,"For reference and study trastuzumab products, mean Cmax of 229.02 and 210.68 μg/mL and AUC0-336 of 24298.29 and 25809.33 (μg × h/mL), respectively, were obtained.",A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30082554/),[h·μg] / [ml],25809.33,34085,DB00072,Trastuzumab
,23171545,tumor-to-muscle ratios,"In the BALB/neuT model and in BALB/c nu/nu mice bearing 231/H2N xenografts, tumor accumulation amounted to 12.7 ± 0.67 and 15.0 ± 3.7% of the injected dose/g (%ID/g) of tumor tissue at 72 h, with tumor-to-muscle ratios of 35:1 and 7:1, respectively.",Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23171545/),,35:1,35889,DB00072,Trastuzumab
,23171545,tumor-to-muscle ratios,"In the BALB/neuT model and in BALB/c nu/nu mice bearing 231/H2N xenografts, tumor accumulation amounted to 12.7 ± 0.67 and 15.0 ± 3.7% of the injected dose/g (%ID/g) of tumor tissue at 72 h, with tumor-to-muscle ratios of 35:1 and 7:1, respectively.",Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23171545/),,7:1,35890,DB00072,Trastuzumab
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,67,38013,DB00072,Trastuzumab
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,0,38014,DB00072,Trastuzumab
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,56,38015,DB00072,Trastuzumab
,23969513,Cmin,"In the presence of trastuzumab and docetaxel, the mean pertuzumab Cmin and Cmax in cycle 3 were 63.6 and 183 µg/ml, respectively.",Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23969513/),[μg] / [ml],63.6,38779,DB00072,Trastuzumab
,23969513,Cmax,"In the presence of trastuzumab and docetaxel, the mean pertuzumab Cmin and Cmax in cycle 3 were 63.6 and 183 µg/ml, respectively.",Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23969513/),[μg] / [ml],183,38780,DB00072,Trastuzumab
,30351177,drug-to-antibody ratio (DAR),Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor (DXd) at a drug-to-antibody ratio (DAR) of 7-8.,"Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30351177/),,7-8,40638,DB00072,Trastuzumab
,32819305,Overall response rate,Overall response rate was 49.6% in BCD-022 arm and 43.6% in reference trastuzumab arm.,Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32819305/),%,49.6,41399,DB00072,Trastuzumab
,32819305,Overall response rate,Overall response rate was 49.6% in BCD-022 arm and 43.6% in reference trastuzumab arm.,Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32819305/),%,43.6,41400,DB00072,Trastuzumab
,25377592,area under the concentration-time curve from time zero to infinity (AUC∞),"The mean area under the concentration-time curve from time zero to infinity (AUC∞) was 1,609 µg·day/mL (Test) and 1,330 µg·day/mL (Reference).",A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377592/),[d·μg] / [ml],"1,609",41409,DB00072,Trastuzumab
,25377592,area under the concentration-time curve from time zero to infinity (AUC∞),"The mean area under the concentration-time curve from time zero to infinity (AUC∞) was 1,609 µg·day/mL (Test) and 1,330 µg·day/mL (Reference).",A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377592/),[d·μg] / [ml],"1,330",41410,DB00072,Trastuzumab
more,14507946,trough levels,Trastuzumab trough levels were more than 20 mug/mL by the end of cycle 1.,"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14507946/),[μg] / [ml],20,41489,DB00072,Trastuzumab
,14507946,half-life,"The half-life of trastuzumab was estimated to be 18 to 27 days, although this may be an underestimate.","Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14507946/),d,18 to 27,41490,DB00072,Trastuzumab
,14507946,objective response rate,The investigator-assessed objective response rate was 59% (four complete and 15 partial responses) and seven patients (22%) had stable disease.,"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14507946/),%,59,41491,DB00072,Trastuzumab
,14507946,duration of response,The median duration of response was 10.5 months and median time to progression was 12.2 months.,"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14507946/),month,10.5,41492,DB00072,Trastuzumab
,14507946,time to progression,The median duration of response was 10.5 months and median time to progression was 12.2 months.,"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14507946/),month,12.2,41493,DB00072,Trastuzumab
,28637800,biologic half-life T1/2β,"The median biologic half-life T1/2β was 111 h (range, 78-193 h).","Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28637800/),h,111,43424,DB00072,Trastuzumab
,28637800,biologic whole-body retention half-life,"The median biologic whole-body retention half-life was 370 h (range, 257-578 h).","Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28637800/),h,370,43425,DB00072,Trastuzumab
,28637800,maximum tumor SUV,"The maximum tumor SUV ranged from no to minimal uptake in 3 patients to a median of 6.8 (range, 2.9-22.7) for 20 lesions in 7 patients.","Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28637800/),,no,43426,DB00072,Trastuzumab
,28637800,maximum tumor SUV,"The maximum tumor SUV ranged from no to minimal uptake in 3 patients to a median of 6.8 (range, 2.9-22.7) for 20 lesions in 7 patients.","Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28637800/),,6.8,43427,DB00072,Trastuzumab
,28643558,minimum plasma concentration ( Cmin),"The objective of the present study was to determine the proportion of nonmetastatic HER2-positive breast cancers that do not reach a minimum plasma concentration ( Cmin) of 20 µg/mL after first drug administration, established as therapeutically effective in clinical trials.",Influence of Anthropometric Characteristics in Patients With Her2-Positive Breast Cancer on Initial Plasma Concentrations of Trastuzumab. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28643558/),[μg] / [ml],20,47599,DB00072,Trastuzumab
,28643558,Cmin,"Of 19 patients included, 9 (47.4%) had a mean Cmin of 19.0 µg/mL (±12.1) after the first administration.",Influence of Anthropometric Characteristics in Patients With Her2-Positive Breast Cancer on Initial Plasma Concentrations of Trastuzumab. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28643558/),[μg] / [ml],19.0,47600,DB00072,Trastuzumab
,24350780,absolute bioavailability,The estimated absolute bioavailability of trastuzumab after SC administration in rats was 85.5%.,The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24350780/),%,85.5,48422,DB00072,Trastuzumab
,24350780,mean absorption time,"Following SC administration, 53.1% of the trastuzumab dose was absorbed via a first-order process (mean absorption time: 99.6 h) into the peripheral lymph compartment and 32.4% of the dose was absorbed by a Michaelis-Menten process into the central compartment.",The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24350780/),h,99.6,48423,DB00072,Trastuzumab
,24350780,Recovery,Recovery in thoracic lymph over 30 h was 26.7% after SC and 44.1% after IV administration.,The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24350780/),%,26.7,48424,DB00072,Trastuzumab
,24350780,Recovery,Recovery in thoracic lymph over 30 h was 26.7% after SC and 44.1% after IV administration.,The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24350780/),%,44.1,48425,DB00072,Trastuzumab
,20975068,progression-free survival,"Median progression-free survival was 34 weeks (95% CI, 29.1 to 40.7 weeks).",Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975068/),weeks,34,48656,DB00072,Trastuzumab
,18347007,overall response rate,"Seven patients achieved a partial response (median duration, 19 weeks), giving an overall response rate of 11%.","Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347007/),%,11,49557,DB00072,Trastuzumab
,18347007,time to progression,"Median time to progression and overall survival were 10 and 38 weeks, respectively.","Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347007/),weeks,10,49558,DB00072,Trastuzumab
,18347007,overall survival,"Median time to progression and overall survival were 10 and 38 weeks, respectively.","Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347007/),weeks,38,49559,DB00072,Trastuzumab
,33118153,drug-to-antibody ratio,"Trastuzumab deruxtecan (DS-8201) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate with a novel enzyme-cleavable linker, a topoisomerase I inhibitor payload, and a drug-to-antibody ratio of ≈ 8.",Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33118153/),,8,51407,DB00072,Trastuzumab
,21307819,area,"Single or combination chemotherapy with paclitaxel, docetaxel, carboplatin, and trastuzumab was administered to 9 baboons at a mean (SD) gestational age of 117 (26) days (paclitaxel, 100 mg/m2 [n = 2]; docetaxel, 100 mg/m2 [n = 2]; paclitaxel, 175 mg/m2 with carboplatin, area under the curve of 6 at standard dosage [n = 2] and 50% dosage [n = 1]; docetaxel, 75 mg/m2 with carboplatin, area under the curve 6 [n = 1]; and docetaxel, 75 mg/m2 with trastuzumab, 8 mg/kg [n = 1]).","Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21307819/),,6,54625,DB00072,Trastuzumab
,21307819,transplacental passages,"The transplacental passages of trastuzumab were 85.0% and 3.0%, 2 and 26 hours after trastuzumab infusion, respectively.","Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21307819/),%,85.0,54626,DB00072,Trastuzumab
,21307819,transplacental passages,"The transplacental passages of trastuzumab were 85.0% and 3.0%, 2 and 26 hours after trastuzumab infusion, respectively.","Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21307819/),%,3.0,54627,DB00072,Trastuzumab
,34349115,PFS,"After a median follow-up of 12.4 months, the median PFS was 10.4 months (95% confidence interval, 2.7-19.3).",Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34349115/),month,10.4,54900,DB00072,Trastuzumab
,28388844,drug-to-antibody ratio (DAR),The two approved ADCs (and most ADCs now in the clinic that use a microtubule disrupting agent as the payload) are heterogeneous conjugates with an average drug-to-antibody ratio (DAR) of 3-4 (potentially ranging from 0 to 8 for individual species).,"Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28388844/),,3-4,55177,DB00072,Trastuzumab
,28388844,drug-to-antibody ratio (DAR),The two approved ADCs (and most ADCs now in the clinic that use a microtubule disrupting agent as the payload) are heterogeneous conjugates with an average drug-to-antibody ratio (DAR) of 3-4 (potentially ranging from 0 to 8 for individual species).,"Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28388844/),,0 to 8,55178,DB00072,Trastuzumab
>,30002437,trough plasma concentration (Ctrough),Primary endpoint was percentage of patients with trough plasma concentration (Ctrough) >20 μg/ml at Cycle 5 (Cycle 6 predose).,Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30002437/),[μg] / [ml],20,55339,DB00072,Trastuzumab
>,30002437,Ctrough,"For PF-05280014 vs trastuzumab-EU patients, respectively, 92.1% vs 93.3% had Cycle 5 Ctrough >20 μg/ml; the lower limit of the 95% confidence interval (- 8.02%, 6.49%) for the stratified difference between groups was above the non-inferiority margin (- 12.5%).",Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30002437/),,20,55340,DB00072,Trastuzumab
,30002437,Pathological complete response,Pathological complete response (47.0% vs 50.0%) and central radiology review-assessed objective response (88.1% vs 82.0%) rates were comparable.,Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30002437/),%,47.0,55341,DB00072,Trastuzumab
,30002437,Pathological complete response,Pathological complete response (47.0% vs 50.0%) and central radiology review-assessed objective response (88.1% vs 82.0%) rates were comparable.,Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30002437/),%,50.0,55342,DB00072,Trastuzumab
,30420181,duration of response,"Median (95% confidence interval) duration of response in the 10 and 30 mg/kg cohorts was 12.6 (4.3-20.2) and 16.6 (8.2-not estimable) months, respectively.",Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30420181/),month,12.6,56339,DB00072,Trastuzumab
,30420181,duration of response,"Median (95% confidence interval) duration of response in the 10 and 30 mg/kg cohorts was 12.6 (4.3-20.2) and 16.6 (8.2-not estimable) months, respectively.",Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30420181/),month,16.6,56340,DB00072,Trastuzumab
,33499723,dissociation constant (KD),Our results confirmed that bivalent anti-TfR mAb with an optimal dissociation constant (KD) value (76 nM) among four affinity variants can have up to 10-fold higher transcytosed free mAb exposure in the brain interstitial fluid (bISF) compared to lower and higher affinity mAbs (5 and 174 nM).,Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33499723/),nM,76,58322,DB00072,Trastuzumab
,33499723,dissociation constant (KD),Our results confirmed that bivalent anti-TfR mAb with an optimal dissociation constant (KD) value (76 nM) among four affinity variants can have up to 10-fold higher transcytosed free mAb exposure in the brain interstitial fluid (bISF) compared to lower and higher affinity mAbs (5 and 174 nM).,Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33499723/),,5,58323,DB00072,Trastuzumab
,18594220,Time to progression,"Time to progression was 361 days, with 75.0% of liver metastases and 60% of lung metastases responding to this treatment.",Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594220/),d,361,58428,DB00072,Trastuzumab
,15868146,clearance (CL),"Population estimates from the base model for clearance (CL) and volume of distribution of the central compartment (V1) of trastuzumab were 0.225 L/day, and 2.95 L, respectively.",Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15868146/),[l] / [d],0.225,61518,DB00072,Trastuzumab
,15868146,volume of distribution of the central compartment (V1),"Population estimates from the base model for clearance (CL) and volume of distribution of the central compartment (V1) of trastuzumab were 0.225 L/day, and 2.95 L, respectively.",Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15868146/),l,2.95,61519,DB00072,Trastuzumab
,15868146,terminal halflife (t1/2),Estimated terminal halflife (t1/2) based on the population estimate was 28.5 days.,Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15868146/),d,28.5,61520,DB00072,Trastuzumab
,29777007,absorbed dose,"The calculated absorbed dose of 64Cu-NOTA-trastuzumab was 0.048 mGy/MBq for the heart, 0.079 mGy/MBq for the liver, and 0.047 mGy/MBq for the spleen.",Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777007/),[mgy] / [Mbq],0.048,66299,DB00072,Trastuzumab
,29777007,absorbed dose,"The calculated absorbed dose of 64Cu-NOTA-trastuzumab was 0.048 mGy/MBq for the heart, 0.079 mGy/MBq for the liver, and 0.047 mGy/MBq for the spleen.",Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777007/),[mgy] / [Mbq],0.079,66300,DB00072,Trastuzumab
,29777007,absorbed dose,"The calculated absorbed dose of 64Cu-NOTA-trastuzumab was 0.048 mGy/MBq for the heart, 0.079 mGy/MBq for the liver, and 0.047 mGy/MBq for the spleen.",Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777007/),[mgy] / [Mbq],0.047,66301,DB00072,Trastuzumab
,12881383,area under the plasma concentration-time curve (AUC(0-24 h)),The area under the plasma concentration-time curve (AUC(0-24 h)) was 1230 +/- 318 [mean +/- standard deviation (SD)] at the first cycle and 1287 +/- 385 h.,Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),,1230,66532,DB00072,Trastuzumab
,12881383,area under the plasma concentration-time curve (AUC(0-24 h)),The area under the plasma concentration-time curve (AUC(0-24 h)) was 1230 +/- 318 [mean +/- standard deviation (SD)] at the first cycle and 1287 +/- 385 h.,Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),,1287,66533,DB00072,Trastuzumab
,12881383,maximum plasma concentration (C(max)),"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),[μg] / [l],1303,66534,DB00072,Trastuzumab
,12881383,maximum plasma concentration (C(max)),"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),[μg] / [l],1229,66535,DB00072,Trastuzumab
,12881383,terminal elimination half-life,"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),h,12.5,66536,DB00072,Trastuzumab
,12881383,terminal elimination half-life,"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),h,11.5,66537,DB00072,Trastuzumab
,28294622,DoL,"Overall, our work shows a DoL of 0.3 or less for non-site-specifically labeled antibodies (with a Poisson distribution) is ideal for limiting the impact of NIR fluorophores on antibody pharmacokinetics.",Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28294622/),,0.3,66651,DB00072,Trastuzumab
,34426442,C max ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,0.99,69654,DB00072,Trastuzumab
,34426442,C max ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,1.04,69655,DB00072,Trastuzumab
,34426442,AUC17d ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,1.22,69656,DB00072,Trastuzumab
,34426442,AUC17d ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,1.18,69657,DB00072,Trastuzumab
,33528890,maximum tolerated dose,The maximum tolerated dose was determined to be 3.6 mg/kg.,"Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33528890/),[mg] / [kg],3.6,72385,DB00072,Trastuzumab
,26714164,central volume of distribution,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),l,2.1,72701,DB00072,Trastuzumab
,26714164,peripheral volume of distribution,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),l,1.3,72702,DB00072,Trastuzumab
,26714164,intercompartment clearance,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),[l] / [day],0.36,72703,DB00072,Trastuzumab
,26714164,elimination half-life,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),d,11.8,72704,DB00072,Trastuzumab
,26714164,clearance,Typical clearance was 0.22 l day(-1) (19%) and its value was increased with tumour size.,Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),[l] / [day],0.22,72705,DB00072,Trastuzumab
,27452985,Overall response rate,Overall response rate was 38.9% and median progression-free survival was 274 days.,Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27452985/),%,38.9,80900,DB00072,Trastuzumab
,27452985,progression-free survival,Overall response rate was 38.9% and median progression-free survival was 274 days.,Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27452985/),d,274,80901,DB00072,Trastuzumab
,28764748,overall response rate,The overall response rate was 22% (2/9 patients had partial response) and stable disease was seen in 56% (5/9 patients).,A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28764748/),%,22,81098,DB00072,Trastuzumab
,28764748,progression-free survival,The median progression-free survival was 20 weeks (range 8-55).,A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28764748/),weeks,20,81099,DB00072,Trastuzumab
,15013588,time to progression,Median time to progression was 36 weeks.,"Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013588/),weeks,36,86142,DB00072,Trastuzumab
>,15013588,shed antigen,Serum Her2 shed antigen was >15 ng/ml in 27/ 288 (9%) patients.,"Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013588/),[ng] / [ml],15,86143,DB00072,Trastuzumab
,30610367,cerebrospinal fluid trough concentration,"For trastuzumab, the mean cerebrospinal fluid trough concentration of 53.4 mg/L reached relevant levels, enabling the stabilization of the metastases.",A successful compartmental approach for the treatment of breast cancer brain metastases. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30610367/),[mg] / [l],53.4,87658,DB00072,Trastuzumab
,27052654,MTD,"Administered with T-DM1 (3.6 mg/kg), the docetaxel MTD was 60 mg/m(2) in MBC.",Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052654/),,60,90200,DB00072,Trastuzumab
,27052654,objective response rate,"In MBC (median prior systemic agents = 5), the objective response rate was 80.0% (20/25; 95% confidence interval [CI] 59.3-93.2) and the median progression-free survival was 13.8 months (range, 1.6-33.5).",Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052654/),%,80,90201,DB00072,Trastuzumab
,27052654,progression-free survival,"In MBC (median prior systemic agents = 5), the objective response rate was 80.0% (20/25; 95% confidence interval [CI] 59.3-93.2) and the median progression-free survival was 13.8 months (range, 1.6-33.5).",Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052654/),month,13.8,90202,DB00072,Trastuzumab
,25370464,objective response,"Overall, objective response and disease control rates were 11% and 39%, respectively, with median progression-free survival 111.0 days (95% confidence interval, 56.0-274.0).",Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25370464/),%,11,92341,DB00072,Trastuzumab
,25370464,disease control rates,"Overall, objective response and disease control rates were 11% and 39%, respectively, with median progression-free survival 111.0 days (95% confidence interval, 56.0-274.0).",Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25370464/),%,39,92342,DB00072,Trastuzumab
,25370464,progression-free survival,"Overall, objective response and disease control rates were 11% and 39%, respectively, with median progression-free survival 111.0 days (95% confidence interval, 56.0-274.0).",Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25370464/),d,111.0,92343,DB00072,Trastuzumab
,25370464,MTD,"The MTD of afatinib was 20 mg daily combined with the recommended weekly dose of trastuzumab, with 1 of 6 patients showing DLTs in the dose escalation.",Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25370464/),mg,20,92344,DB00072,Trastuzumab
,31183514,"steady-state serum trough (minimum) concentration (Cmin,ss)","The mean observed pertuzumab steady-state serum trough (minimum) concentration (Cmin,ss) ± standard deviation was 114 ± 51.8 μg/mL.",Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183514/),[μg] / [ml],114,92836,DB00072,Trastuzumab
≥,31183514,"Cmin,ss","The target pertuzumab Cmin,ss of ≥ 20 μg/mL was reached in 99.3% of patients at Cycle 5 (steady state) and beyond.",Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31183514/),[μg] / [ml],20,92837,DB00072,Trastuzumab
,32191233,total sample processing time,"A pharmacokinetics (PK) study dosing Herceptin in rat was analyzed by both the membrane and the standard method with a total sample processing time of 4 h and 20 h, respectively.",Improving the throughput of immunoaffinity purification and enzymatic digestion of therapeutic proteins using membrane-immobilized reagent technology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32191233/),h,4,97191,DB00072,Trastuzumab
,32191233,total sample processing time,"A pharmacokinetics (PK) study dosing Herceptin in rat was analyzed by both the membrane and the standard method with a total sample processing time of 4 h and 20 h, respectively.",Improving the throughput of immunoaffinity purification and enzymatic digestion of therapeutic proteins using membrane-immobilized reagent technology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32191233/),h,20,97192,DB00072,Trastuzumab
,30350178,MTD,The MTD of afatinib in combination with the recommended 3-weekly dose of trastuzumab was 20 mg daily.,Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30350178/),,20,98272,DB00072,Trastuzumab
,10604742,trough serum concentration,Target trough serum concentration has been set at 10 microg ml(-1) based on in vitro observations.,Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604742/),[μg] / [ml],10,100169,DB00072,Trastuzumab
,10604742,minimum trough serum concentrations,"The mean value of minimum trough serum concentrations at each dose level were 3.58 +/- 0.63, 6.53 +/- 5.26, 40.2 +/- 7.12 and 87.9 +/- 23.5 microg ml(-1) respectively.",Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604742/),[μg] / [ml],3.58,100170,DB00072,Trastuzumab
,10604742,minimum trough serum concentrations,"The mean value of minimum trough serum concentrations at each dose level were 3.58 +/- 0.63, 6.53 +/- 5.26, 40.2 +/- 7.12 and 87.9 +/- 23.5 microg ml(-1) respectively.",Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604742/),[μg] / [ml],6.53,100171,DB00072,Trastuzumab
,10604742,minimum trough serum concentrations,"The mean value of minimum trough serum concentrations at each dose level were 3.58 +/- 0.63, 6.53 +/- 5.26, 40.2 +/- 7.12 and 87.9 +/- 23.5 microg ml(-1) respectively.",Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604742/),[μg] / [ml],40.2,100172,DB00072,Trastuzumab
,10604742,minimum trough serum concentrations,"The mean value of minimum trough serum concentrations at each dose level were 3.58 +/- 0.63, 6.53 +/- 5.26, 40.2 +/- 7.12 and 87.9 +/- 23.5 microg ml(-1) respectively.",Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604742/),[μg] / [ml],87.9,100173,DB00072,Trastuzumab
,31305270,steady-state Cmax,"In 15 patients, mean steady-state Cmax and Cmin pertuzumab serum concentrations (368 ± 177 μg/ml, and 122 ± 47 μg/ml, respectively) were numerically higher than observed previously in a pharmacokinetic analysis of the global population in APHINITY and in patients treated in the metastatic setting.",Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31305270/),[μg] / [ml],368,100953,DB00072,Trastuzumab
,31305270,Cmin,"In 15 patients, mean steady-state Cmax and Cmin pertuzumab serum concentrations (368 ± 177 μg/ml, and 122 ± 47 μg/ml, respectively) were numerically higher than observed previously in a pharmacokinetic analysis of the global population in APHINITY and in patients treated in the metastatic setting.",Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31305270/),[μg] / [ml],122,100954,DB00072,Trastuzumab
,28950146,Disease control rate,"Disease control rate was 79% [95% confidence interval [CI] 57-92%], one patient obtained a complete remission, and six additional patients experienced stable disease for ≥ 24 weeks (clinical benefit rate of 29% [95% CI 12-51%]).",PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28950146/),%,79,102992,DB00072,Trastuzumab
,28950146,clinical benefit rate,"Disease control rate was 79% [95% confidence interval [CI] 57-92%], one patient obtained a complete remission, and six additional patients experienced stable disease for ≥ 24 weeks (clinical benefit rate of 29% [95% CI 12-51%]).",PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28950146/),%,29,102993,DB00072,Trastuzumab
,15800309,overall response rate,The overall response rate was 19% (23% in patients with measurable centrally confirmed immunohistochemistry [IHC] 3+ and/or fluorescence in situ hybridization [FISH] -positive disease) and clinical benefit rate (complete and partial responses plus stable disease for at least 6 months) was 33% (36% in patients with measurable centrally confirmed IHC 3+ and/or FISH-positive disease).,"Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15800309/),%,19,105200,DB00072,Trastuzumab
,15800309,overall response rate,The overall response rate was 19% (23% in patients with measurable centrally confirmed immunohistochemistry [IHC] 3+ and/or fluorescence in situ hybridization [FISH] -positive disease) and clinical benefit rate (complete and partial responses plus stable disease for at least 6 months) was 33% (36% in patients with measurable centrally confirmed IHC 3+ and/or FISH-positive disease).,"Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15800309/),%,23,105201,DB00072,Trastuzumab
,15800309,clinical benefit rate,The overall response rate was 19% (23% in patients with measurable centrally confirmed immunohistochemistry [IHC] 3+ and/or fluorescence in situ hybridization [FISH] -positive disease) and clinical benefit rate (complete and partial responses plus stable disease for at least 6 months) was 33% (36% in patients with measurable centrally confirmed IHC 3+ and/or FISH-positive disease).,"Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15800309/),%,33,105202,DB00072,Trastuzumab
,15800309,clinical benefit rate,The overall response rate was 19% (23% in patients with measurable centrally confirmed immunohistochemistry [IHC] 3+ and/or fluorescence in situ hybridization [FISH] -positive disease) and clinical benefit rate (complete and partial responses plus stable disease for at least 6 months) was 33% (36% in patients with measurable centrally confirmed IHC 3+ and/or FISH-positive disease).,"Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15800309/),%,36,105203,DB00072,Trastuzumab
,15800309,time to progression,"Median time to progression was 3.4 months (range, 0.6 to 23.6 months).","Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15800309/),month,3.4,105204,DB00072,Trastuzumab
,30467591,total CL,"During treatment, linear clearance (CL) dominated, resulting in a total CL of 0.173-0.337 L/day, which is similar to other IgG1 monoclonal antibodies.","Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30467591/),[l] / [d],0.173-0.337,108671,DB00072,Trastuzumab
,23852665,maximum tolerated dose,First-in-man phase I study set the maximum tolerated dose at 3.6 mg/kg given intravenously on a 3-weekly regimen.,"The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23852665/),,3,110307,DB00072,Trastuzumab
,12525520,overall response rate,An overall response rate of 7.3% included one complete and two partial responses.,"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525520/),%,7.3,110773,DB00072,Trastuzumab
,12525520,progression-free interval,"Median treatment duration was 8 weeks (range, 2 to 104 weeks), and median progression-free interval was 2.0 months.","Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12525520/),month,2.0,110774,DB00072,Trastuzumab
,23458409,IC(50),"The IC(50) value was found to be 20.23 ± 1.95, 3.74 ± 0.98, 0.08 ± 0.4 μg/ml for the marketed preparation of DTX, TPGS liposomes and trastuzumab-conjugated TPGS liposomes, respectively after 24 h incubation with SK-BR-3 cells.",Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458409/),[μg] / [ml],20.23,112401,DB00072,Trastuzumab
,23458409,IC(50),"The IC(50) value was found to be 20.23 ± 1.95, 3.74 ± 0.98, 0.08 ± 0.4 μg/ml for the marketed preparation of DTX, TPGS liposomes and trastuzumab-conjugated TPGS liposomes, respectively after 24 h incubation with SK-BR-3 cells.",Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458409/),[μg] / [ml],3.74,112402,DB00072,Trastuzumab
,23458409,IC(50),"The IC(50) value was found to be 20.23 ± 1.95, 3.74 ± 0.98, 0.08 ± 0.4 μg/ml for the marketed preparation of DTX, TPGS liposomes and trastuzumab-conjugated TPGS liposomes, respectively after 24 h incubation with SK-BR-3 cells.",Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458409/),[μg] / [ml],0.08,112403,DB00072,Trastuzumab
≈,24100444,T½,"It was determined that 68Ga-DOTA-F(ab')2-trastuzumab was well tolerated, with a T½ of ≈ 3.6 ± 0.9 h; the critical organ was the kidney, with a mean dose of 0.383 cGy/37 MBq; and tumor targeting was seen in 4/8 patients with HER2-positive disease.",Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24100444/),h,3.6,113669,DB00072,Trastuzumab
,31655131,absolute bioavailability,After SC administration cetuximab absolute bioavailability increased from 67 % to 80 % in the presence of rHuPH20.,Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655131/),%,67,115438,DB00072,Trastuzumab
,31655131,absolute bioavailability,After SC administration cetuximab absolute bioavailability increased from 67 % to 80 % in the presence of rHuPH20.,Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655131/),%,80,115439,DB00072,Trastuzumab
,31655131,absolute bioavailability,"In contrast, co-administration with rHuPH20 did not lead to increases in plasma exposure for trastuzumab after SC or ID administration, most likely reflecting the fact that the reported absolute bioavailability of trastuzumab (in the absence of rHuPH20) is high (∼77-99 %).",Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31655131/),%,∼77-99,115440,DB00072,Trastuzumab
,29635147,residual intra-cerebrospinal fluid concentration,The mean residual intra-cerebrospinal fluid concentration of trastuzumab was 27.9 mg/L for the 150 mg dose level.,Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29635147/),[mg] / [l],27.9,127030,DB00072,Trastuzumab
,31102024,Cmax,"In MARIANNE (N = 375), mean ± standard deviation population pharmacokinetic model-predicted Cycle 1 Cmax for T-DM1 conjugate was 74.4 ± 10.1 µg/mL, Cycle 1 Ctrough was 1.34 ± 0.802 µg/mL, and area under the concentration-time curve from time zero to infinity after first dose (AUCinf) was 338 ± 69.5 µg*day/mL.",Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31102024/),[μg] / [ml],74.4,135125,DB00072,Trastuzumab
,31102024,Ctrough,"In MARIANNE (N = 375), mean ± standard deviation population pharmacokinetic model-predicted Cycle 1 Cmax for T-DM1 conjugate was 74.4 ± 10.1 µg/mL, Cycle 1 Ctrough was 1.34 ± 0.802 µg/mL, and area under the concentration-time curve from time zero to infinity after first dose (AUCinf) was 338 ± 69.5 µg*day/mL.",Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31102024/),[μg] / [ml],1.34,135126,DB00072,Trastuzumab
,31102024,area under the concentration-time curve from time zero to infinity after first dose (AUCinf),"In MARIANNE (N = 375), mean ± standard deviation population pharmacokinetic model-predicted Cycle 1 Cmax for T-DM1 conjugate was 74.4 ± 10.1 µg/mL, Cycle 1 Ctrough was 1.34 ± 0.802 µg/mL, and area under the concentration-time curve from time zero to infinity after first dose (AUCinf) was 338 ± 69.5 µg*day/mL.",Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31102024/),[d·μg] / [ml],338,135127,DB00072,Trastuzumab
,31102024,Cmax,"In the pertuzumab plus T-DM1 arm, mean model-predicted Cycle 1 pertuzumab Cmax, Ctrough, and AUCinf were 276 ± 50.0 µg/mL, 64.8 ± 17.9 μg/mL, and 4470 ± 1360 µg*day/mL, respectively.",Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31102024/),[μg] / [ml],276,135128,DB00072,Trastuzumab
,31102024,Ctrough,"In the pertuzumab plus T-DM1 arm, mean model-predicted Cycle 1 pertuzumab Cmax, Ctrough, and AUCinf were 276 ± 50.0 µg/mL, 64.8 ± 17.9 μg/mL, and 4470 ± 1360 µg*day/mL, respectively.",Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31102024/),[μg] / [ml],64.8,135129,DB00072,Trastuzumab
,31102024,AUCinf,"In the pertuzumab plus T-DM1 arm, mean model-predicted Cycle 1 pertuzumab Cmax, Ctrough, and AUCinf were 276 ± 50.0 µg/mL, 64.8 ± 17.9 μg/mL, and 4470 ± 1360 µg*day/mL, respectively.",Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31102024/),[d·μg] / [ml],4470,135130,DB00072,Trastuzumab
,17595342,terminal plasma half-life,"Although the 100 residue HAP fusion showed a behavior very similar to the unfused Fab fragment, with a terminal plasma half-life of ca. 2 h, the 200 residue HAPylated Fab fragment gave rise to a significantly prolonged half-life of ca. 6 h.",Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17595342/),h,2,137476,DB00072,Trastuzumab
,17595342,half-life,"Although the 100 residue HAP fusion showed a behavior very similar to the unfused Fab fragment, with a terminal plasma half-life of ca. 2 h, the 200 residue HAPylated Fab fragment gave rise to a significantly prolonged half-life of ca. 6 h.",Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17595342/),h,6,137477,DB00072,Trastuzumab
,29043411,linear clearance (CL),"The final population model estimated linear clearance (CL) of 0.79 L/day, volume of distribution in the central compartment (V c) of 4.48 L, distribution clearance (Q) of 0.62 L/day, volume of distribution in the peripheral compartment (V p) of 1.49 L, nonlinear CL of 2.06 L/day, and KM of 1.63 μg/mL.",Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043411/),[l] / [d],0.79,138348,DB00072,Trastuzumab
,29043411,volume of distribution in the central compartment (V c),"The final population model estimated linear clearance (CL) of 0.79 L/day, volume of distribution in the central compartment (V c) of 4.48 L, distribution clearance (Q) of 0.62 L/day, volume of distribution in the peripheral compartment (V p) of 1.49 L, nonlinear CL of 2.06 L/day, and KM of 1.63 μg/mL.",Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043411/),l,4.48,138349,DB00072,Trastuzumab
,29043411,distribution clearance (Q),"The final population model estimated linear clearance (CL) of 0.79 L/day, volume of distribution in the central compartment (V c) of 4.48 L, distribution clearance (Q) of 0.62 L/day, volume of distribution in the peripheral compartment (V p) of 1.49 L, nonlinear CL of 2.06 L/day, and KM of 1.63 μg/mL.",Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043411/),[l] / [d],0.62,138350,DB00072,Trastuzumab
,29043411,volume of distribution in the peripheral compartment (V p),"The final population model estimated linear clearance (CL) of 0.79 L/day, volume of distribution in the central compartment (V c) of 4.48 L, distribution clearance (Q) of 0.62 L/day, volume of distribution in the peripheral compartment (V p) of 1.49 L, nonlinear CL of 2.06 L/day, and KM of 1.63 μg/mL.",Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043411/),l,1.49,138351,DB00072,Trastuzumab
,29043411,CL,"The final population model estimated linear clearance (CL) of 0.79 L/day, volume of distribution in the central compartment (V c) of 4.48 L, distribution clearance (Q) of 0.62 L/day, volume of distribution in the peripheral compartment (V p) of 1.49 L, nonlinear CL of 2.06 L/day, and KM of 1.63 μg/mL.",Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043411/),[l] / [d],2.06,138352,DB00072,Trastuzumab
,29043411,KM,"The final population model estimated linear clearance (CL) of 0.79 L/day, volume of distribution in the central compartment (V c) of 4.48 L, distribution clearance (Q) of 0.62 L/day, volume of distribution in the peripheral compartment (V p) of 1.49 L, nonlinear CL of 2.06 L/day, and KM of 1.63 μg/mL.",Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043411/),[μg] / [ml],1.63,138353,DB00072,Trastuzumab
,30361524,overall response rate (ORR),"With MM-302 ≥ 30 mg/m2, overall response rate (ORR) was 13% and median progression-free survival (mPFS) 7.4 months (95% CI: 3·5-10·9) in all arms.","Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30361524/),%,13,138929,DB00072,Trastuzumab
,30361524,progression-free survival,"With MM-302 ≥ 30 mg/m2, overall response rate (ORR) was 13% and median progression-free survival (mPFS) 7.4 months (95% CI: 3·5-10·9) in all arms.","Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30361524/),month,7,138930,DB00072,Trastuzumab
,33547646,V1,"Apparent volumes of distribution were close to physiological volumes (V1 = 3.25 L, V2 = 0.644 L, for serum and CSF, respectively).",Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547646/),l,3.25,141113,DB00072,Trastuzumab
,33547646,V2,"Apparent volumes of distribution were close to physiological volumes (V1 = 3.25 L, V2 = 0.644 L, for serum and CSF, respectively).",Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547646/),l,0.644,141114,DB00072,Trastuzumab
,33547646,k12,Estimated (constant) transfer from serum to CSF was very slow (k12 = 0.264 mg/day) whereas estimated half-life of transfer from CSF to serum was rapid (2.2 days).,Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547646/),[mg] / [d],0.264,141115,DB00072,Trastuzumab
,33547646,half-life of transfer,Estimated (constant) transfer from serum to CSF was very slow (k12 = 0.264 mg/day) whereas estimated half-life of transfer from CSF to serum was rapid (2.2 days).,Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547646/),d,2.2,141116,DB00072,Trastuzumab
,33547646,mean residence times,"From the individual parameters of patients, a single i.t. administration of 150 mg of trastuzumab corresponded to median mean residence times of 3.8 days and 15.6 days in CSF and serum, respectively.",Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547646/),d,3.8,141117,DB00072,Trastuzumab
,33547646,mean residence times,"From the individual parameters of patients, a single i.t. administration of 150 mg of trastuzumab corresponded to median mean residence times of 3.8 days and 15.6 days in CSF and serum, respectively.",Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547646/),d,15.6,141118,DB00072,Trastuzumab
,34245336,elimination half-lives,Their central volume of distributions (Vc) increased with body surface area and their elimination half-lives were shorter (~14 days) than previously reported (~26-28 days).,Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34245336/),d,14,146117,DB00072,Trastuzumab
,34245336,elimination half-lives,Their central volume of distributions (Vc) increased with body surface area and their elimination half-lives were shorter (~14 days) than previously reported (~26-28 days).,Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34245336/),d,26-28,146118,DB00072,Trastuzumab
,32963641,tmax,Plasma concentrations of rHuPH20 increased during the 5-minute intravenous infusion (median tmax = 6 minutes from intravenous initiation) followed by a rapid plasma clearance (t1/2 ∼10 minutes from intravenous initiation).,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32963641/),min,6,147448,DB00072,Trastuzumab
,32963641,tmax,Plasma hyaluronan concentrations increased with dose and time (tmax range = 45‒120 minutes from intravenous initiation) and returned to baseline within 1 week of administration.,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32963641/),min,45‒120,147449,DB00072,Trastuzumab
,26645407,bioavailability,"Trastuzumab PK was described by a two-compartment model with parallel linear and nonlinear elimination and first-order SC absorption, with a bioavailability of 77 %.","Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),%,77,151103,DB00072,Trastuzumab
,26645407,total clearance (CL),Estimated total clearance (CL) values were 0.18-0.22 L/day for steady-state trough/peak concentrations of 75-148 µg/mL; the estimate for central volume of distribution was 2.9 L.,"Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),[l] / [d],0.18-0.22,151104,DB00072,Trastuzumab
,26645407,steady-state trough/peak concentrations,Estimated total clearance (CL) values were 0.18-0.22 L/day for steady-state trough/peak concentrations of 75-148 µg/mL; the estimate for central volume of distribution was 2.9 L.,"Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),[μg] / [ml],75-148,151105,DB00072,Trastuzumab
,26645407,central volume of distribution,Estimated total clearance (CL) values were 0.18-0.22 L/day for steady-state trough/peak concentrations of 75-148 µg/mL; the estimate for central volume of distribution was 2.9 L.,"Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),l,2.9,151106,DB00072,Trastuzumab
,26645407,steady-state trough concentrations,"A fixed 600 mg SC dose of trastuzumab provides the desired exposure, with steady-state trough concentrations (35-123 μg/mL for the 5th-95th percentiles) above the historical target concentration of 20 μg/mL for efficacy.","Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),[μg] / [ml],35-123,151107,DB00072,Trastuzumab
,26645407,steady-state trough concentrations,"A fixed 600 mg SC dose of trastuzumab provides the desired exposure, with steady-state trough concentrations (35-123 μg/mL for the 5th-95th percentiles) above the historical target concentration of 20 μg/mL for efficacy.","Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),,20,151108,DB00072,Trastuzumab
,26917603,objective response rate,"The objective response rate in 73 treated patients was 38.4% (90% confidence interval, 28.8-48.6%), exceeding the prespecified boundary for an objective response rate > 20%.","A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26917603/),%,38.4,153229,DB00072,Trastuzumab
>,26917603,objective response rate,"The objective response rate in 73 treated patients was 38.4% (90% confidence interval, 28.8-48.6%), exceeding the prespecified boundary for an objective response rate > 20%.","A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26917603/),%,20,153230,DB00072,Trastuzumab
,26917603,progression-free survival,"After 6.5 months' median follow-up, median progression-free survival was 5.6 months (95% confidence interval, 4.6-8.2).","A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26917603/),month,5.6,153231,DB00072,Trastuzumab
,26917603,overall survival,"After 28.9 months' median follow-up, median overall survival was 30.5 months (95% confidence interval 25.2-not reached).","A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26917603/),month,30.5,153232,DB00072,Trastuzumab
,25157044,Non-decay-corrected cumulative urinary excretion,Non-decay-corrected cumulative urinary excretion was 6% or less in 24 h (2.3 half-lives).,Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25157044/),%,6,159107,DB00072,Trastuzumab
,25157044,half-lives,Non-decay-corrected cumulative urinary excretion was 6% or less in 24 h (2.3 half-lives).,Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25157044/),,2.3,159108,DB00072,Trastuzumab
,28662406,progression-free survival,"ORR was 34.8% (95% CI: 16.4-57.3, n = 23), and median progression-free survival was 42.6 weeks (95% CI: 20.3-51.9, n = 30).",First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28662406/),weeks,42.6,159249,DB00072,Trastuzumab
,28662406,Clinical benefit rate,Clinical benefit rate was 60.9% (95% CI: 16.4-57.3).,First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28662406/),%,60.9,159250,DB00072,Trastuzumab
,15933419,Cmax,Cmax was 22.2 microg/ml (t(max) = 24 min) in the MONO and 24.6 microg/ml (t(max) = 23 min) in the TMAB schedule.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),[μg] / [ml],22.2,161705,DB00072,Trastuzumab
,15933419,Cmax,Cmax was 22.2 microg/ml (t(max) = 24 min) in the MONO and 24.6 microg/ml (t(max) = 23 min) in the TMAB schedule.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),[μg] / [ml],24.6,161706,DB00072,Trastuzumab
,15933419,t(max),Cmax was 22.2 microg/ml (t(max) = 24 min) in the MONO and 24.6 microg/ml (t(max) = 23 min) in the TMAB schedule.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),min,24,161707,DB00072,Trastuzumab
,15933419,t(max),Cmax was 22.2 microg/ml (t(max) = 24 min) in the MONO and 24.6 microg/ml (t(max) = 23 min) in the TMAB schedule.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),[μg] / [ml],24.6,161708,DB00072,Trastuzumab
,15933419,t(max),Cmax was 22.2 microg/ml (t(max) = 24 min) in the MONO and 24.6 microg/ml (t(max) = 23 min) in the TMAB schedule.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),min,23,161709,DB00072,Trastuzumab
,15933419,t1/2el,Gemcitabine distributed rapidly from plasma within a few minutes and was eliminated with a t1/2el of about 80 min in both arms of the study.,Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),min,80,161710,DB00072,Trastuzumab
,15933419,t1/2appin,"The metabolite difluorodeoxyuridine (dFdU) appeared in plasma with t1/2appin = 12.8 min (MONO) or t1/2appin = 10.2 min (TMAB) reaching a mean peak concentration of 35.9 microg/ml (MONO) or 30.4 microg/ml (TMAB), respectively.",Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),min,12.8,161711,DB00072,Trastuzumab
,15933419,t1/2appin,"The metabolite difluorodeoxyuridine (dFdU) appeared in plasma with t1/2appin = 12.8 min (MONO) or t1/2appin = 10.2 min (TMAB) reaching a mean peak concentration of 35.9 microg/ml (MONO) or 30.4 microg/ml (TMAB), respectively.",Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),min,10.2,161712,DB00072,Trastuzumab
,15933419,peak concentration,"The metabolite difluorodeoxyuridine (dFdU) appeared in plasma with t1/2appin = 12.8 min (MONO) or t1/2appin = 10.2 min (TMAB) reaching a mean peak concentration of 35.9 microg/ml (MONO) or 30.4 microg/ml (TMAB), respectively.",Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),[μg] / [ml],35.9,161713,DB00072,Trastuzumab
,15933419,peak concentration,"The metabolite difluorodeoxyuridine (dFdU) appeared in plasma with t1/2appin = 12.8 min (MONO) or t1/2appin = 10.2 min (TMAB) reaching a mean peak concentration of 35.9 microg/ml (MONO) or 30.4 microg/ml (TMAB), respectively.",Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933419/),[μg] / [ml],30.4,161714,DB00072,Trastuzumab
,32710210,TSCs,TSCs ranged from 1.0 to 9.8 µg/mL (n = 7) for PF-06804103 and from 4.7 to 29 µg/mL (n = 5) for T-DM1.,"Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32710210/),[μg] / [ml],1.0 to 9.8,164120,DB00072,Trastuzumab
,32710210,TSCs,TSCs ranged from 1.0 to 9.8 µg/mL (n = 7) for PF-06804103 and from 4.7 to 29 µg/mL (n = 5) for T-DM1.,"Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32710210/),[μg] / [ml],4.7 to 29,164121,DB00072,Trastuzumab
,28498781,maximum tolerated dose,"The dose-limiting toxicity was grade 3 diarrhea, which occurred in two patients administered 480 mg of pyrotinib; thus, the maximum tolerated dose was 400 mg.","Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28498781/),,400,167272,DB00072,Trastuzumab
,28498781,overall response rate,"The overall response rate was 50.0% (18 of 36), and the clinical benefit rate (complete response + partial response + stable disease ≥ 24 weeks) was 61.1% (22 of 36).","Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28498781/),%,50.0,167273,DB00072,Trastuzumab
,28498781,progression-free survival,"The median progression-free survival was 35.4 weeks (95% CI, 23.3 to 40.0 weeks).","Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28498781/),weeks,35.4,167274,DB00072,Trastuzumab
,28498781,overall response rate,The overall response rate was 83.3% (10 of 12) in trastuzumab-naive patients and 33.3% (eight of 24) in trastuzumab-pretreated patients.,"Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28498781/),%,83.3,167275,DB00072,Trastuzumab
,28498781,overall response rate,The overall response rate was 83.3% (10 of 12) in trastuzumab-naive patients and 33.3% (eight of 24) in trastuzumab-pretreated patients.,"Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28498781/),%,33.3,167276,DB00072,Trastuzumab
,27423671,AUCinf,"NCA pharmacokinetic parameters (T-DM1, total trastuzumab, DM1) were comparable across ethnic groups; mean cycle 1 T-DM1 AUCinf was 475, 442, and 518 day µg/mL for white (n = 461), Asian (n = 68), and others (n = 57), respectively.",Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423671/),[d·μg] / [ml],475,169971,DB00072,Trastuzumab
,27423671,AUCinf,"NCA pharmacokinetic parameters (T-DM1, total trastuzumab, DM1) were comparable across ethnic groups; mean cycle 1 T-DM1 AUCinf was 475, 442, and 518 day µg/mL for white (n = 461), Asian (n = 68), and others (n = 57), respectively.",Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423671/),[d·μg] / [ml],442,169972,DB00072,Trastuzumab
,27423671,AUCinf,"NCA pharmacokinetic parameters (T-DM1, total trastuzumab, DM1) were comparable across ethnic groups; mean cycle 1 T-DM1 AUCinf was 475, 442, and 518 day µg/mL for white (n = 461), Asian (n = 68), and others (n = 57), respectively.",Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423671/),[d·μg] / [ml],518,169973,DB00072,Trastuzumab
,12855614,objective response rate,"The overall Phase II intent-to-treat objective response rate was 65% (complete responses, 12%).",A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12855614/),%,65,170541,DB00072,Trastuzumab
,12855614,complete responses,"The overall Phase II intent-to-treat objective response rate was 65% (complete responses, 12%).",A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12855614/),%,12,170542,DB00072,Trastuzumab
,12855614,overall survival,"The median overall survival was 22 months, and the median time to progression was 6 months.",A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12855614/),month,22,170543,DB00072,Trastuzumab
,12855614,time to progression,"The median overall survival was 22 months, and the median time to progression was 6 months.",A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12855614/),month,6,170544,DB00072,Trastuzumab
,24229395,maximum blood radioactivity concentration,"Peak blood level of the radiolabeled antibody, determined by decay corrected counts, was <23% injected dose at 63 hours; maximum blood radioactivity concentration was 6.3nCi/mL at 18 hours.",Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24229395/),[nci] / [ml],6.3,172995,DB00072,Trastuzumab
≤,24229395,urinary excretion,Cumulative urinary excretion was ≤6% in 2.3 half-lives.,Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24229395/),%,6,172996,DB00072,Trastuzumab
,24229395,urinary excretion,Cumulative urinary excretion was ≤6% in 2.3 half-lives.,Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24229395/),,2.3,172997,DB00072,Trastuzumab
,24229395,maximum external exposure rate,The maximum external exposure rate immediately post-infusion at skin contact over the abdomen averaged 7.67 mR/h and dropped to 0.67 mR/h by 24 hours.,Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24229395/),[mr] / [h],7.67,172998,DB00072,Trastuzumab
,24229395,maximum external exposure rate,The maximum external exposure rate immediately post-infusion at skin contact over the abdomen averaged 7.67 mR/h and dropped to 0.67 mR/h by 24 hours.,Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24229395/),[mr] / [h],0.67,172999,DB00072,Trastuzumab
,24229395,T1/2,The data points correlate closely with 212Pb physical decay (T1/2=10.6 hours).,Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24229395/),h,10.6,173000,DB00072,Trastuzumab
,21519841,CL,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],24.9,174812,DB00072,Trastuzumab
,21519841,V1,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,8.48,174813,DB00072,Trastuzumab
,21519841,Q2,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],50.7,174814,DB00072,Trastuzumab
,21519841,V2,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,"1,320",174815,DB00072,Trastuzumab
,21519841,Q3,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],66.1,174816,DB00072,Trastuzumab
,21519841,V3,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,62.4,174817,DB00072,Trastuzumab
,21519841,CL,"The population pharmacokinetic parameters were CL = 27.7 L/h, V = 357 L, and the absorption constant, ka = 0.44 h(-1).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],27.7,174818,DB00072,Trastuzumab
,21519841,V,"The population pharmacokinetic parameters were CL = 27.7 L/h, V = 357 L, and the absorption constant, ka = 0.44 h(-1).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,357,174819,DB00072,Trastuzumab
,21519841,"absorption constant, ka","The population pharmacokinetic parameters were CL = 27.7 L/h, V = 357 L, and the absorption constant, ka = 0.44 h(-1).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),1/[h],0.44,174820,DB00072,Trastuzumab
,34045226,payload drug-to-antibody ratio,"ASN004 is a 5T4-targeted antibody-drug conjugate (ADC) that incorporates a novel single-chain Fv-Fc antibody and Dolaflexin drug-linker technology, with an Auristatin F hydroxypropylamide payload drug-to-antibody ratio of approximately 10-12.","ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34045226/),,10-12,175032,DB00072,Trastuzumab
,24960402,Cmin,Mean pertuzumab Cmin at day 43 was 40.0 μg ml(-1) (s.d.: 17.3) in Arm A and 62.7 μg ml(-1) (29.1) in Arm B.,"A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24960402/),[μg] / [ml],40.0,176260,DB00072,Trastuzumab
,24960402,Cmin,Mean pertuzumab Cmin at day 43 was 40.0 μg ml(-1) (s.d.: 17.3) in Arm A and 62.7 μg ml(-1) (29.1) in Arm B.,"A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24960402/),[μg] / [ml],62.7,176261,DB00072,Trastuzumab
,33126339,maximum serum concentration,"Among 11 Chinese patients, mean (±standard deviation) PK parameters (maximum serum concentration, 77.6 ± 17.4 μg/mL; clearance 11.0 ± 2.6 mL/d/kg; terminal half-life 3.8 ± 1.0 days) were similar to those previously reported in Western and Japanese patients.",A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33126339/),[μg] / [ml],77.6,177168,DB00072,Trastuzumab
,33126339,clearance,"Among 11 Chinese patients, mean (±standard deviation) PK parameters (maximum serum concentration, 77.6 ± 17.4 μg/mL; clearance 11.0 ± 2.6 mL/d/kg; terminal half-life 3.8 ± 1.0 days) were similar to those previously reported in Western and Japanese patients.",A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33126339/),[ml] / [d·kg],11.0,177169,DB00072,Trastuzumab
,33126339,terminal half-life,"Among 11 Chinese patients, mean (±standard deviation) PK parameters (maximum serum concentration, 77.6 ± 17.4 μg/mL; clearance 11.0 ± 2.6 mL/d/kg; terminal half-life 3.8 ± 1.0 days) were similar to those previously reported in Western and Japanese patients.",A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33126339/),d,3.8,177170,DB00072,Trastuzumab
,27171605,T1/2,"Study 1 versus study 2 showed similar serum concentration post-injection (mean 42.4±7.8 %ID/L vs. 44.7±12.6 %ID/L) and similar T1/2 (single exponential 46.1 vs. 44.2 hours), P>0.5.",Copper-64 trastuzumab PET imaging: a reproducibility study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27171605/),h,46.1,177509,DB00072,Trastuzumab
,27171605,T1/2,"Study 1 versus study 2 showed similar serum concentration post-injection (mean 42.4±7.8 %ID/L vs. 44.7±12.6 %ID/L) and similar T1/2 (single exponential 46.1 vs. 44.2 hours), P>0.5.",Copper-64 trastuzumab PET imaging: a reproducibility study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27171605/),h,44.2,177510,DB00072,Trastuzumab
,27171605,volume of distribution,The volume of distribution (median 2.50 L) was in the range reported for trastuzumab and close to the estimated plasma volume of 2.60 L.,Copper-64 trastuzumab PET imaging: a reproducibility study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27171605/),l,2.50,177511,DB00072,Trastuzumab
,27171605,plasma volume,The volume of distribution (median 2.50 L) was in the range reported for trastuzumab and close to the estimated plasma volume of 2.60 L.,Copper-64 trastuzumab PET imaging: a reproducibility study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27171605/),l,2.60,177512,DB00072,Trastuzumab
,29882016,MTD,"The monotherapy MTD for capsule A and SDS sachet was determined to be 1000 and 1200 mg/day, respectively.","Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29882016/),[mg] / [d],1000,178620,DB00072,Trastuzumab
,29882016,MTD,"The monotherapy MTD for capsule A and SDS sachet was determined to be 1000 and 1200 mg/day, respectively.","Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29882016/),[mg] / [d],1200,178621,DB00072,Trastuzumab
,29882016,MTD,The MTD of BEZ235 in combination with trastuzumab was 600 mg/day.,"Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29882016/),[mg] / [d],600,178622,DB00072,Trastuzumab
,29882016,MTD,The MTD of BEZ235 as single agent was 1200 and 600 mg/day with trastuzumab.,"Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29882016/),[mg] / [d],1200,178623,DB00072,Trastuzumab
,29882016,MTD,The MTD of BEZ235 as single agent was 1200 and 600 mg/day with trastuzumab.,"Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29882016/),[mg] / [d],600,178624,DB00072,Trastuzumab
,11521722,overall response rates,"This was followed by two phase II clinical trials of fixed-dose trastuzumab either as a single-agent or in combination with cisplatin in 46 and 39 patients, which produced overall response rates of 11.6%, and 24.3%, respectively.",Phase I and II clinical trials of trastuzumab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521722/),%,11.6,184074,DB00072,Trastuzumab
,11521722,overall response rates,"This was followed by two phase II clinical trials of fixed-dose trastuzumab either as a single-agent or in combination with cisplatin in 46 and 39 patients, which produced overall response rates of 11.6%, and 24.3%, respectively.",Phase I and II clinical trials of trastuzumab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521722/),%,24.3,184075,DB00072,Trastuzumab
,11521722,overall response rate,The overall response rate was 21% when assessed in evaluable patients by the investigators and 15% when analyzed on an intent-to-treat basis by an independent Response Evaluation Committee.,Phase I and II clinical trials of trastuzumab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521722/),%,21,184076,DB00072,Trastuzumab
,11521722,overall response rate,The overall response rate was 21% when assessed in evaluable patients by the investigators and 15% when analyzed on an intent-to-treat basis by an independent Response Evaluation Committee.,Phase I and II clinical trials of trastuzumab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521722/),%,15,184077,DB00072,Trastuzumab
,22648179,MTD,"Twenty-eight patients received weekly T-DM1, and the MTD was determined to be 2.4 mg/kg.",A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648179/),[mg] / [kg],2.4,184999,DB00072,Trastuzumab
,22648179,clinical benefit rate,"Objective partial tumor responses were reported in 13 (46.4%) patients; the median duration of response was 18.6 months, and the 6-month clinical benefit rate was 57.1%.",A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648179/),,57,185000,DB00072,Trastuzumab
,33255658,overall response rate,"Among all evaluable patients, the overall response rate was 40.0% (95%CI, 16.3-67.7) with a median duration of response of 6.9 months (95%CI, 4.8-9.1).","Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255658/),%,40.0,186214,DB00072,Trastuzumab
,33255658,duration of response,"Among all evaluable patients, the overall response rate was 40.0% (95%CI, 16.3-67.7) with a median duration of response of 6.9 months (95%CI, 4.8-9.1).","Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255658/),month,6.9,186215,DB00072,Trastuzumab
,33255658,Clinical benefit rate,"Clinical benefit rate was 66.7% (95%CI, 38.4-88.2) and median progression-free survival was 7.2 months (95%CI, 4.5-9.6).","Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255658/),%,66.7,186216,DB00072,Trastuzumab
,33255658,progression-free survival,"Clinical benefit rate was 66.7% (95%CI, 38.4-88.2) and median progression-free survival was 7.2 months (95%CI, 4.5-9.6).","Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255658/),month,7.2,186217,DB00072,Trastuzumab
,30316083,entrapment efficiency,"The particle size and entrapment efficiency of conventional, non-targeted as well as targeted nanoparticles were in the range of 126-186 nm and 74-78% respectively.",Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30316083/),%,74-78,188583,DB00072,Trastuzumab
,12843231,Tumor uptake,Tumor uptake for the irrelevant mAb was 0.4 +/- 0.1.,Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12843231/),,0.4,192199,DB00072,Trastuzumab
,12843231,absorbed dose to the kidneys,The absorbed dose to the kidneys was 0.31 Gy/MBq (90)Y-trastuzumab.,Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12843231/),[gy] / [Mbq],0.31,192200,DB00072,Trastuzumab
,12843231,Absorbed dose to tumors,Absorbed dose to tumors varied from 0.10 Gy/MBq for radius = 0.1 mm to 3.7 Gy/MBq for radius = 5 mm.,Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12843231/),[gy] / [Mbq],0.10,192201,DB00072,Trastuzumab
,12843231,Absorbed dose to tumors,Absorbed dose to tumors varied from 0.10 Gy/MBq for radius = 0.1 mm to 3.7 Gy/MBq for radius = 5 mm.,Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12843231/),[gy] / [Mbq],3.7,192202,DB00072,Trastuzumab
,32651200,drug-to-antibody ratio (DAR),"This construct, termed CAT-01-106, has a drug-to-antibody ratio (DAR) of 1.8, approximately half the average DAR of T-DM1, which comprises a mixture of antibodies variously conjugated with DARs ranging from 0 to 8.",A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32651200/),,1.8,193193,DB00072,Trastuzumab
,25394095,concentration,Plasma concentrations of raltegravir in eight patients showed a median concentration of 143 ng/mL (79-455).,"Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25394095/),[ng] / [ml],143,195476,DB00072,Trastuzumab
,25644368,absolute bioavailability,"After sc administration, initial plasma pharmacokinetics and lymphatic exposure were also similar between PEG-trastuzumab and trastuzumab, but the absolute bioavailability of PEG-trastuzumab was 100% when compared to 86.1% bioavailability for trastuzumab.",PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25644368/),%,100,196816,DB00072,Trastuzumab
,25644368,absolute bioavailability,"After sc administration, initial plasma pharmacokinetics and lymphatic exposure were also similar between PEG-trastuzumab and trastuzumab, but the absolute bioavailability of PEG-trastuzumab was 100% when compared to 86.1% bioavailability for trastuzumab.",PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25644368/),%,86.1,196817,DB00072,Trastuzumab
,25644368,bioavailability,"After sc administration, initial plasma pharmacokinetics and lymphatic exposure were also similar between PEG-trastuzumab and trastuzumab, but the absolute bioavailability of PEG-trastuzumab was 100% when compared to 86.1% bioavailability for trastuzumab.",PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25644368/),%,86.1,196818,DB00072,Trastuzumab
,23553425,deconjugation clearance,The deconjugation clearance of T-DM1 was estimated to be ~0.4 L/day.,An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23553425/),[l] / [d],0.4,200244,DB00072,Trastuzumab
,23553425,Proteolytic degradation clearances,Proteolytic degradation clearances for T-DM1 and trastuzumab were similar (~0.3 L/day).,An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23553425/),[l] / [d],0.3,200245,DB00072,Trastuzumab
>,25145670,IC50,"(131)I-radioiodination of two synthetic tubulysin A analogues, the less potent TUB-OH (IC50 > 100 nmol/L) and the potent TUB-OMOM (IC50, ~1 nmol/L), and their direct covalent conjugation to (89)Zr-trastuzumab were established.",Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145670/),[nM] / [l],100,203695,DB00072,Trastuzumab
,25145670,IC50,"(131)I-radioiodination of two synthetic tubulysin A analogues, the less potent TUB-OH (IC50 > 100 nmol/L) and the potent TUB-OMOM (IC50, ~1 nmol/L), and their direct covalent conjugation to (89)Zr-trastuzumab were established.",Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145670/),[nM] / [l],1,203696,DB00072,Trastuzumab
,25145670,DAR,An average DAR of 2 and 4 conferred pharmacokinetics and tumor-targeting behavior similar to parental trastuzumab.,Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145670/),,2,203697,DB00072,Trastuzumab
,25145670,DAR,An average DAR of 2 and 4 conferred pharmacokinetics and tumor-targeting behavior similar to parental trastuzumab.,Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145670/),,4,203698,DB00072,Trastuzumab
,29373094,bpCR rates,"The bpCR rates were 51.7% and 42.0% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,51.7,209179,DB00072,Trastuzumab
,29373094,bpCR rates,"The bpCR rates were 51.7% and 42.0% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,42.0,209180,DB00072,Trastuzumab
,29373094,total pathologic complete response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,45.8,209181,DB00072,Trastuzumab
,29373094,total pathologic complete response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,35.8,209182,DB00072,Trastuzumab
,29373094,overall response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,96.3,209183,DB00072,Trastuzumab
,29373094,overall response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,91.2,209184,DB00072,Trastuzumab
,31138588,progression-free survival (PFS),The median progression-free survival (PFS) was 22.1 months (95% CI: 9.0-26.2 months).,"Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31138588/),month,22.1,210109,DB00072,Trastuzumab
,21953571,maximum tolerated dose,"T-DM1 has been tested as a single agent in a phase I and 2 phase II studies of patients with heavily pretreated metastatic breast cancer (MBC), with the maximum tolerated dose established at 3.6 mg/kg intravenously for every-3-week dosing.","Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953571/),mg,3,215651,DB00072,Trastuzumab
,21953571,clearance,"Population estimates (interindividual variability [IIV]) for pharmacokinetic parameters were clearance, 0.7 L/d (21.0%); central compartment volume (V(c)), 3.33 L (13.2%); peripheral compartment volume (V(p)), 0.89 L (50.4%); and intercompartmental clearance, 0.78 L/d.","Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953571/),[l] / [d],0.7,215652,DB00072,Trastuzumab
,21953571,central compartment volume (V(c)),"Population estimates (interindividual variability [IIV]) for pharmacokinetic parameters were clearance, 0.7 L/d (21.0%); central compartment volume (V(c)), 3.33 L (13.2%); peripheral compartment volume (V(p)), 0.89 L (50.4%); and intercompartmental clearance, 0.78 L/d.","Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953571/),l,3.33,215653,DB00072,Trastuzumab
,21953571,peripheral compartment volume (V(p)),"Population estimates (interindividual variability [IIV]) for pharmacokinetic parameters were clearance, 0.7 L/d (21.0%); central compartment volume (V(c)), 3.33 L (13.2%); peripheral compartment volume (V(p)), 0.89 L (50.4%); and intercompartmental clearance, 0.78 L/d.","Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953571/),l,0.89,215654,DB00072,Trastuzumab
,21953571,intercompartmental clearance,"Population estimates (interindividual variability [IIV]) for pharmacokinetic parameters were clearance, 0.7 L/d (21.0%); central compartment volume (V(c)), 3.33 L (13.2%); peripheral compartment volume (V(p)), 0.89 L (50.4%); and intercompartmental clearance, 0.78 L/d.","Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953571/),[l] / [d],0.78,215655,DB00072,Trastuzumab
,23618841,t1/2α,"(111)In-DTPA-trastuzumab Fab fragments exhibited a biphasic elimination from the blood and plasma with t1/2α=11.9h and 7.5h, respectively, and t1/2β=26.6 and 20.7h, respectively.",Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618841/),h,11.9,222844,DB00072,Trastuzumab
,23618841,t1/2α,"(111)In-DTPA-trastuzumab Fab fragments exhibited a biphasic elimination from the blood and plasma with t1/2α=11.9h and 7.5h, respectively, and t1/2β=26.6 and 20.7h, respectively.",Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618841/),h,7.5,222845,DB00072,Trastuzumab
,23618841,t1/2β,"(111)In-DTPA-trastuzumab Fab fragments exhibited a biphasic elimination from the blood and plasma with t1/2α=11.9h and 7.5h, respectively, and t1/2β=26.6 and 20.7h, respectively.",Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618841/),h,26.6,222846,DB00072,Trastuzumab
,23618841,t1/2β,"(111)In-DTPA-trastuzumab Fab fragments exhibited a biphasic elimination from the blood and plasma with t1/2α=11.9h and 7.5h, respectively, and t1/2β=26.6 and 20.7h, respectively.",Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618841/),h,20.7,222847,DB00072,Trastuzumab
,23618841,effective dose,The mean effective dose was 0.146mSv/MBq (10.8mSv for 74MBq).,Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618841/),[msv] / [Mbq],0.146,222848,DB00072,Trastuzumab
,23618841,effective dose,The mean effective dose was 0.146mSv/MBq (10.8mSv for 74MBq).,Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618841/),msv,10.8,222849,DB00072,Trastuzumab
,18690878,volume of distribution,"Trastuzumab pharmacokinetics are characterized by a low systemic clearance, a low volume of distribution (4l) and a very long half-life (28 days) comparable to that of endogenous immunoglobulins G.",Clinical pharmacology of trastuzumab. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18690878/),l,4,223477,DB00072,Trastuzumab
,18690878,half-life,"Trastuzumab pharmacokinetics are characterized by a low systemic clearance, a low volume of distribution (4l) and a very long half-life (28 days) comparable to that of endogenous immunoglobulins G.",Clinical pharmacology of trastuzumab. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18690878/),d,28,223478,DB00072,Trastuzumab
,16631082,half,The objective of this study was to determine the cytotoxic effectiveness of trastuzumab labeled with the 7.2-h half-life alpha-particle emitter 211At.,In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631082/),h,7.2,227543,DB00072,Trastuzumab
,16631082,SF,"With external beam irradiation, the 2-Gy SF for BT-474, SKBr-3 and MCF7/HER2-18 cells was 0.78, 0.53 and 0.64 Gy, respectively.",In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631082/),gy,0.78,227544,DB00072,Trastuzumab
,16631082,SF,"With external beam irradiation, the 2-Gy SF for BT-474, SKBr-3 and MCF7/HER2-18 cells was 0.78, 0.53 and 0.64 Gy, respectively.",In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631082/),gy,0.53,227545,DB00072,Trastuzumab
,16631082,SF,"With external beam irradiation, the 2-Gy SF for BT-474, SKBr-3 and MCF7/HER2-18 cells was 0.78, 0.53 and 0.64 Gy, respectively.",In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16631082/),gy,0.64,227546,DB00072,Trastuzumab
,23722548,plasma half-life (t1/2β,Pharmacokinetic studies in mice revealed that hSGZ exhibited a biexponential clearance from plasma with a rapid initial clearance (t1/2α = 1.26 hours) followed by a seven-fold longer plasma half-life (t1/2β = 7.29 hours).,"Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23722548/),h,7.29,231661,DB00072,Trastuzumab
,23722548,uptake,"At 24, 48, and 72 hours after injection, uptake of the hSGZ into tumors was 5.1, 4.8, and 4.7%ID/g, with a tumor-to-muscle ratio of 5.6, 6.2, and 9.0, respectively.","Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23722548/),[%id] / [g],5.1,231662,DB00072,Trastuzumab
,23722548,uptake,"At 24, 48, and 72 hours after injection, uptake of the hSGZ into tumors was 5.1, 4.8, and 4.7%ID/g, with a tumor-to-muscle ratio of 5.6, 6.2, and 9.0, respectively.","Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23722548/),[%id] / [g],4.8,231663,DB00072,Trastuzumab
,23722548,uptake,"At 24, 48, and 72 hours after injection, uptake of the hSGZ into tumors was 5.1, 4.8, and 4.7%ID/g, with a tumor-to-muscle ratio of 5.6, 6.2, and 9.0, respectively.","Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23722548/),[%id] / [g],4.7,231664,DB00072,Trastuzumab
,23722548,tumor-to-muscle ratio,"At 24, 48, and 72 hours after injection, uptake of the hSGZ into tumors was 5.1, 4.8, and 4.7%ID/g, with a tumor-to-muscle ratio of 5.6, 6.2, and 9.0, respectively.","Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23722548/),,5.6,231665,DB00072,Trastuzumab
,23722548,tumor-to-muscle ratio,"At 24, 48, and 72 hours after injection, uptake of the hSGZ into tumors was 5.1, 4.8, and 4.7%ID/g, with a tumor-to-muscle ratio of 5.6, 6.2, and 9.0, respectively.","Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23722548/),,6.2,231666,DB00072,Trastuzumab
,23722548,tumor-to-muscle ratio,"At 24, 48, and 72 hours after injection, uptake of the hSGZ into tumors was 5.1, 4.8, and 4.7%ID/g, with a tumor-to-muscle ratio of 5.6, 6.2, and 9.0, respectively.","Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23722548/),,9.0,231667,DB00072,Trastuzumab
,27630807,tumor/blood ratio,Immunopositron emission tomography imaging and biodistribution with 89Zr-L5-trastuzumab revealed high tumor to background ratios (tumor/blood ratio: 14.2 ± 2.25) and a high tumor specificity that was comparable to the performance of 89Zr-DFO-trastuzumab.,Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27630807/),,14.2,236800,DB00072,Trastuzumab
,18490651,OTR,"The OTR was 1,000 mg lapatinib with standard weekly trastuzumab.",Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18490651/),mg,"1,000",236927,DB00072,Trastuzumab
more,25434923,plasma terminal half-life,"The plasma terminal half-life was more than 24h, supporting once daily dosing.","Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25434923/),h,24,237297,DB00072,Trastuzumab
,19261664,terminal half-life,The serum concentration of pertuzumab declined slowly (terminal half-life is approximately 3 weeks).,"Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19261664/),weeks,3,238666,DB00072,Trastuzumab
,20026806,trough concentration,"Median estimated trough concentration of trastuzumab at the end of 3 weeks of the intensive loading regimen (total of 18 mg/kg of trastuzumab administered) of cycle 1 was 119 mg/L, which is higher than steady-state trough concentrations with a conventional weekly or every-3-week regimen (64.9 or 47.3 mg/L, respectively).",Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20026806/),[mg] / [l],119,239858,DB00072,Trastuzumab
,20026806,steady-state trough concentrations,"Median estimated trough concentration of trastuzumab at the end of 3 weeks of the intensive loading regimen (total of 18 mg/kg of trastuzumab administered) of cycle 1 was 119 mg/L, which is higher than steady-state trough concentrations with a conventional weekly or every-3-week regimen (64.9 or 47.3 mg/L, respectively).",Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20026806/),[mg] / [l],64.9,239859,DB00072,Trastuzumab
,20026806,steady-state trough concentrations,"Median estimated trough concentration of trastuzumab at the end of 3 weeks of the intensive loading regimen (total of 18 mg/kg of trastuzumab administered) of cycle 1 was 119 mg/L, which is higher than steady-state trough concentrations with a conventional weekly or every-3-week regimen (64.9 or 47.3 mg/L, respectively).",Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20026806/),[mg] / [l],47.3,239860,DB00072,Trastuzumab
,20026806,response rate,"In patients with measurable disease (n = 47), response rate was 23.4%.",Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20026806/),%,23.4,239861,DB00072,Trastuzumab
,20026806,time to progression,Median time to progression was 7.7 months (in all patients).,Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20026806/),month,7.7,239862,DB00072,Trastuzumab
,22884505,C(trough),The geometric mean presurgery C(trough) was 51·8 μg/mL (coefficient of variation 52·5%) in the intravenous group and 69·0 μg/mL (55·8%) in the subcutaneous group.,"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884505/),[μg] / [ml],51·8,240404,DB00072,Trastuzumab
,22884505,C(trough),The geometric mean presurgery C(trough) was 51·8 μg/mL (coefficient of variation 52·5%) in the intravenous group and 69·0 μg/mL (55·8%) in the subcutaneous group.,"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884505/),[μg] / [ml],69·0,240405,DB00072,Trastuzumab
,16621915,affinities,"For rat and rabbit albumin, affinities ranged from 0.04 to 2.5 microM.",The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621915/),μM,0.04 to 2.5,243000,DB00072,Trastuzumab
,16621915,clearance,Fab with 0.5 microM affinity for albumin of up to 4 days in humans with a clearance of 76 ml/h.,The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621915/),[ml] / [h],76,243001,DB00072,Trastuzumab
,21107682,progression-free survival,"ORR was 19.1%, with a disease control rate of 83.0% and median progression-free survival of 30.7 weeks.",Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107682/),weeks,30.7,252471,DB00072,Trastuzumab
,22864874,overall response rate,"All patients were evaluable, and the overall response rate was 73.3 % (95 % CI 54.1-87.7).",A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22864874/),%,73.3,252774,DB00072,Trastuzumab
,22864874,progression-free survival,The median progression-free survival was 11.3 months (95 % CI 9.4-21.0).,A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22864874/),month,11.3,252775,DB00072,Trastuzumab
,15534084,overall survival,"At median follow-up of 34 (13-58) months, all HRPBC patients remain alive and free of disease; the MBC group has event-free survival and overall survival rates of 45 and 70%, respectively.",Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15534084/),,70,252895,DB00072,Trastuzumab
,27868228,clearance,"Analysis of two blood samples taken 9 and 10 days after docetaxel revealed plasma levels of 4.73 and 4.09 ng ml-1 , respectively, leading to a 79% decreased individual (Bayesian maximum a posteriori) clearance estimate of 9.15 l h-1 , corresponding to an estimated fivefold increase in AUC.",Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27868228/),[l] / [h],9.15,254796,DB00072,Trastuzumab
,24939213,elimination clearance,"T-DM1 elimination clearance was 0.676 L/day, volume of distribution in the central compartment (V c) was 3.127 L, and terminal elimination half-life was 3.94 days.","Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24939213/),[l] / [d],0.676,262229,DB00072,Trastuzumab
,24939213,volume of distribution in the central compartment (V c),"T-DM1 elimination clearance was 0.676 L/day, volume of distribution in the central compartment (V c) was 3.127 L, and terminal elimination half-life was 3.94 days.","Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24939213/),l,3.127,262230,DB00072,Trastuzumab
,24939213,terminal elimination half-life,"T-DM1 elimination clearance was 0.676 L/day, volume of distribution in the central compartment (V c) was 3.127 L, and terminal elimination half-life was 3.94 days.","Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24939213/),d,3.94,262231,DB00072,Trastuzumab
,22690847,half-life,The short range of the α-particles (70 μm) and the short half-life (7.21 h) of the nuclide yield a dose distribution in which the peritoneum is highly irradiated compared with other normal tissues.,Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22690847/),h,7.21,264676,DB00072,Trastuzumab
,27995530,clearance,"The trend of faster clearance was less apparent in cycle 3, with similar T-DM1 clearance across cohorts (mean ± standard deviation 8.16 ± 3.27 [n = 9], 9.74 ± 3.62 [n = 7], and 8.99 and 10.2 [individual values, n = 2] mL/day/kg for the normal, mild, and moderate cohorts, respectively).",A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995530/),[ml] / [d·kg],8.16,265283,DB00072,Trastuzumab
,27995530,clearance,"The trend of faster clearance was less apparent in cycle 3, with similar T-DM1 clearance across cohorts (mean ± standard deviation 8.16 ± 3.27 [n = 9], 9.74 ± 3.62 [n = 7], and 8.99 and 10.2 [individual values, n = 2] mL/day/kg for the normal, mild, and moderate cohorts, respectively).",A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995530/),[ml] / [d·kg],9.74,265284,DB00072,Trastuzumab
,27995530,clearance,"The trend of faster clearance was less apparent in cycle 3, with similar T-DM1 clearance across cohorts (mean ± standard deviation 8.16 ± 3.27 [n = 9], 9.74 ± 3.62 [n = 7], and 8.99 and 10.2 [individual values, n = 2] mL/day/kg for the normal, mild, and moderate cohorts, respectively).",A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995530/),[ml] / [d·kg],8.99,265285,DB00072,Trastuzumab
,27995530,clearance,"The trend of faster clearance was less apparent in cycle 3, with similar T-DM1 clearance across cohorts (mean ± standard deviation 8.16 ± 3.27 [n = 9], 9.74 ± 3.62 [n = 7], and 8.99 and 10.2 [individual values, n = 2] mL/day/kg for the normal, mild, and moderate cohorts, respectively).",A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995530/),[ml] / [d·kg],10.2,265286,DB00072,Trastuzumab
,25001079,CL,"The CL values across doses ranged from 0.193 to 0.350 mL/h/kg (PF-05280014), from 0.200 to 0.346 mL/h/kg (trastuzumab-US), and from 0.193 to 0.335 mL/h/kg (trastuzumab-EU).",Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25001079/),[ml] / [h·kg],0.193 to 0.350,265764,DB00072,Trastuzumab
,25001079,CL,"The CL values across doses ranged from 0.193 to 0.350 mL/h/kg (PF-05280014), from 0.200 to 0.346 mL/h/kg (trastuzumab-US), and from 0.193 to 0.335 mL/h/kg (trastuzumab-EU).",Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25001079/),[ml] / [h·kg],0.200 to 0.346,265765,DB00072,Trastuzumab
,25001079,CL,"The CL values across doses ranged from 0.193 to 0.350 mL/h/kg (PF-05280014), from 0.200 to 0.346 mL/h/kg (trastuzumab-US), and from 0.193 to 0.335 mL/h/kg (trastuzumab-EU).",Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25001079/),[ml] / [h·kg],0.193 to 0.335,265766,DB00072,Trastuzumab
,25001079,V ss,"V ss values across doses ranged from 84.9 to 120 mL/kg (PF-05280014), 86.7 to 130 mL/kg (trastuzumab-US), and 85.4 to 116 mL/kg (trastuzumab-EU).",Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25001079/),[ml] / [kg],84.9 to 120,265767,DB00072,Trastuzumab
,25001079,V ss,"V ss values across doses ranged from 84.9 to 120 mL/kg (PF-05280014), 86.7 to 130 mL/kg (trastuzumab-US), and 85.4 to 116 mL/kg (trastuzumab-EU).",Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25001079/),[ml] / [kg],86.7 to 130,265768,DB00072,Trastuzumab
,25001079,V ss,"V ss values across doses ranged from 84.9 to 120 mL/kg (PF-05280014), 86.7 to 130 mL/kg (trastuzumab-US), and 85.4 to 116 mL/kg (trastuzumab-EU).",Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25001079/),[ml] / [kg],85.4 to 116,265769,DB00072,Trastuzumab
,30018811,terminal half-life (t1/2),"Compared with trastuzumab, the PK parameters were dose dependent, with a mean terminal half-life (t1/2) of 263±99 hours for the 720 mg dose.","Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30018811/),h,263,266918,DB00072,Trastuzumab
,14973048,survival time,"Median survival time was 145 days as opposed to 78 days, and 31% of the recipients remained tumor free 2 months after therapy was terminated versus 0% in the Herceptin group.","Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973048/),d,145,270291,DB00072,Trastuzumab
,14973048,survival time,"Median survival time was 145 days as opposed to 78 days, and 31% of the recipients remained tumor free 2 months after therapy was terminated versus 0% in the Herceptin group.","Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973048/),d,78,270292,DB00072,Trastuzumab
,20421541,maximum-tolerated dose (MTD),Transient thrombocytopenia was dose-limiting at 4.8 mg/kg; the maximum-tolerated dose (MTD) was 3.6 mg/kg.,"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20421541/),[mg] / [kg],3.6,273492,DB00072,Trastuzumab
,20421541,half-life,"The half-life of T-DM1 at the MTD was 3.5 days, with peak DM1 levels < 10 ng/mL.","Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20421541/),d,3.5,273493,DB00072,Trastuzumab
,20421541,confirmed response rate,The confirmed response rate in patients with measurable disease at the MTD (n = 9) was 44%.,"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20421541/),%,44,273494,DB00072,Trastuzumab
,33727230,terminal plasma half-life,"Administration of 1HE alone was rapidly eliminated with a terminal plasma half-life of 1.2 hours, while coadministrations of 1HE with trastuzumab had a terminal half-life of 56 hours.",Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33727230/),h,1.2,274145,DB00072,Trastuzumab
,33727230,terminal half-life,"Administration of 1HE alone was rapidly eliminated with a terminal plasma half-life of 1.2 hours, while coadministrations of 1HE with trastuzumab had a terminal half-life of 56 hours.",Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33727230/),h,56,274146,DB00072,Trastuzumab
